XML 27 R20.htm IDEA: XBRL DOCUMENT v3.26.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2026
Single reporting segment  
Segment Reporting [Line Items]  
Schedule of Segment Reporting

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to the consolidated net loss for the three and nine months ended September 30, 2026 and 2025 is included at the bottom of the table below (in thousands):

 

 

For the Three Months
Ended September 30,

 

 

For the Nine Months
Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

6,526

 

 

$

9,363

 

 

$

17,632

 

 

$

26,600

 

Tegoprubart - other development programs

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(168

)

Manufacturing

 

 

6,867

 

 

 

1,736

 

 

 

21,814

 

 

 

11,031

 

Personnel-related expenses

 

 

4,323

 

 

 

3,664

 

 

 

12,221

 

 

 

10,808

 

Stock-based compensation

 

 

1,924

 

 

 

2,428

 

 

 

7,280

 

 

 

7,986

 

Other segment items*

 

 

2,032

 

 

 

1,879

 

 

 

6,775

 

 

 

5,510

 

Total operating expenses

 

 

21,672

 

 

 

19,070

 

 

 

65,722

 

 

 

61,767

 

Loss from operations

 

 

(21,672

)

 

 

(19,070

)

 

 

(65,722

)

 

 

(61,767

)

Other income, net

 

 

714

 

 

 

1,047

 

 

 

2,694

 

 

 

3,680

 

Change in fair value of warrant liabilities

 

 

17,025

 

 

 

564

 

 

 

(11,560

)

 

 

22,917

 

Net loss

 

$

(3,933

)

 

$

(17,459

)

 

$

(74,588

)

 

$

(35,170

)

* Other segment items included in total operating expenses primarily consist of consulting, professional fees, facilities, insurance and information technology.